NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between August 8, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/iovance-biotherapeutics-in ...

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to allegations of misleading statements and failure to disclose material adverse facts about the company's growth potential [1]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from August 8, 2024, to May 8, 2025, Iovance provided overly positive statements while concealing significant issues regarding its ability to meet demand for its treatments [1]. - Key factors leading to the company's reduced revenue guidance included maintenance of the iCTC, lower than expected Proleukin sales, and the variable pace of treatment initiation by ATCs [1]. Financial Impact - Following the announcement of reduced revenue guidance on July 25, 2024, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [1]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [3].

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between August 8, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/iovance-biotherapeut ...

NEW YORK, May 19, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025.So What: If you purchased Iovance securities during the Class Period y ...

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for misleading statements made during the Class Period from May 9, 2024, to May 8, 2025, potentially affecting investors' financial interests [1][4]. Group 1: Lawsuit Details - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to longer timelines and higher patient drop-offs [4]. - It is claimed that these issues resulted in increased costs and decreased revenue for Iovance, contradicting the company's positive statements about its business and operations [4]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors in this case, highlighting its track record of recovering significant amounts for investors [5]. - Investors are advised to select qualified legal counsel with a proven history in leadership roles within class actions [5]. - The firm has achieved notable settlements, including over $438 million for investors in 2019 alone, and has been consistently ranked among the top firms in securities class action settlements [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to significant declines in revenue and misleading statements made by the company regarding its business operations and prospects [2][4]. Financial Performance - Iovance reported a quarterly total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a substantial decline [5]. - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [5]. Legal Proceedings - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Iovance made materially false and misleading statements and failed to disclose adverse facts about its business, including issues with new Authorized Treatment Centers (ATCs) and patient treatment timelines [4]. Market Reaction - Following the release of the disappointing financial results, Iovance's share price fell by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, with unusually high trading volume [6].

Core Viewpoint - Julie & Holleman LLP is investigating potential claims against Iovance Biotherapeutics, Inc. and its executives due to recent losses suffered by the company's stockholders [1][2]. Group 1: Legal Investigation - A complaint filed in federal court alleges that Iovance and its executives misled investors by exaggerating the company's financial prospects and downplaying risk factors affecting growth potential [2]. - The complaint specifically claims that the company concealed its inability to generate demand and was ill-equipped to capitalize on existing demand for its treatments through its network of approved treatment centers [2]. Group 2: Firm Background - Julie & Holleman LLP is a boutique law firm specializing in shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations [4]. - The firm's attorneys have a track record of securing hundreds of millions of dollars for aggrieved companies and their shareholders [4].

Core Points - A class action has been filed against Iovance Biotherapeutics, Inc. for allegedly misleading investors regarding its business prospects during the class period from May 9, 2024, to May 8, 2025 [1][2] - The complaint highlights several issues, including delays in treatment timelines at new Authorized Treatment Centers (ATCs), ineffective patient identification and selection, and the resulting higher costs and lower revenue [2] - Iovance reported a significant decline in quarterly product revenue, dropping from $73.7 million to $49.3 million, and revised its full-year revenue guidance down by over 40% [3] Company Performance - Iovance's first quarter 2025 financial results showed total product revenue of $49.3 million, a decrease of approximately 33% from the previous quarter [3] - The company's full fiscal year 2025 revenue guidance was reduced from a range of $450 million - $475 million to $250 million - $300 million, indicating a substantial downward revision [3] Legal Proceedings - Shareholders interested in participating in the class action must file their papers by July 14, 2025, to serve as lead plaintiff [4] - The class action allows shareholders to recover losses without needing to actively participate in the case [4]

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly providing misleading statements about its growth potential and failing to capitalize on demand for its treatments during the class period from May 9, 2024, to May 8, 2025 [1][3]. Company Performance - Iovance announced its financial results for Q2 2024 on July 25, 2024, and reduced its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance that reduced capacity, lower-than-expected Proleukin sales, and the variable pace of treatment initiation [4]. - Following the announcement of reduced guidance, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [4]. Legal Proceedings - The lawsuit is on behalf of all individuals and entities that purchased Iovance securities during the specified class period, with a deadline of July 14, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that the company concealed material adverse facts regarding its ability to meet demand for its treatments [3]. Investor Information - Investors who suffered losses or have questions regarding the lawsuit can contact the law firm Bragar Eagel & Squire, P.C. for more information [5].